Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study
Open Access
- 1 January 2021
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (1), 123-134
- https://doi.org/10.1111/jdv.16431
Abstract
Background: APPRECIATE is a multinational, observational, retrospective, cross-sectional study in patients treated for psoriasis with apremilast, an oral phosphodiesterase 4 inhibitor. Objectives: To describe the characteristics of patients with psoriasis treated with apremilast in the clinical setting, to evaluate real-world outcomes of psoriasis treatment with apremilast and to better understand the perspectives of patients and physicians on treatment outcomes. Methods: In six European countries, patients with chronic plaque psoriasis treated in clinical practice who could be contacted 6 (+/- 1) months after apremilast initiation were enrolled. Patient characteristics, Dermatology Life Quality Index (DLQI) and Psoriasis Area and Severity Index (PASI) were obtained from medical records when available. Outcomes were evaluated using patient/physician questionnaires. Results: In 480 patients at treatment initiation, mean [median; 95% confidence interval (CI)] PASI and DLQI scores were 12.5 (10.7; 11.6-13.4) and 13.4 (13.0; 11.4-14.2), respectively. At 6 (+/- 1) months, 72.3% of patients (n = 347) continued apremilast treatment [discontinuations: lack of efficacy (13.5%), safety (11.7%), other (2.5%)]. In patients continuing treatment, 48.6% achieved a =75% reduction in PASI score; mean (95% CI) DLQI score was 5.7 (4.5-6.9), and mean (SD) Patient Benefit Index score was 2.8 (1.2). Physicians perceived clinical improvement in 75.6% of patients. Physicians' perspective on overall success of apremilast in meeting expectations correlated with patients' perception of treatment benefit (r = 0.691). Most commonly reported adverse events (>5% of patients) were diarrhoea, nausea and headache. Conclusions: Patients in APPRECIATE reported high disease burden despite more moderate skin involvement than those who enrolled in clinical trials of apremilast. Findings from APPRECIATE demonstrate the real-world value of apremilast for psoriasis treatment, as 7 of 10 patients continued therapy and showed notable improvement in disease severity and quality of life 6 (+/- 1) months after apremilast initiation.This publication has 41 references indexed in Scilit:
- Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011PLOS ONE, 2012
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchiv für dermatologische Forschung, 2010
- The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groupsHealth and Quality of Life Outcomes, 2009
- National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningJournal of the American Academy of Dermatology, 2008
- Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsJournal of the American Academy of Dermatology, 2008
- THE JOURNAL OF DERMATOLOGY Volume 34, 2007The Journal of Dermatology, 2007
- Prevalence of cardiovascular risk factors in patients with psoriasisJournal of the American Academy of Dermatology, 2006
- Hierarchical Construct Validity of the Treatment Satisfaction Questionnaire for Medication (TSQM Version II) among Outpatient Pharmacy ConsumersValue in Health, 2005
- Psoriasis: epidemiology, clinical features, and quality of lifeAnnals Of The Rheumatic Diseases, 2005
- A variable-movement specimen holder for texture studiesJournal of Applied Crystallography, 1973